Free Access
Med Sci (Paris)
Volume 29, Number 12, Décembre 2013
Page(s) 1092 - 1094
Section Nouvelles
Published online 20 December 2013
  1. Baysal BE, Ferrell RE, Willett-Brozick JE, et al. Mutations in SDHD, a mitochondrial complex II gene, in hereditary paraganglioma. Science 2000 ; 287 : 848–851. [CrossRef] [PubMed] [Google Scholar]
  2. Favier J, Gimenez-Roqueplo AP. La génétique des paragangliomes et des phéochromocytomes. Med Sci (Paris) 2012 ; 28 : 625–632. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]
  3. Gimenez-Roqueplo AP, Dahia PL, Robledo M. An update on the genetics of paraganglioma, pheochromocytoma, and associated hereditary syndromes. Horm Metab Res 2012 ; 44 : 328–333. [CrossRef] [PubMed] [Google Scholar]
  4. Amar L, Baudin E, Burnichon N, et al. Succinate dehydrogenase B gene mutations predict survival in patients with malignant pheochromocytomas or paragangliomas. J Clin Endocrinol Metab 2007 ; 92 : 3822–3828. [CrossRef] [PubMed] [Google Scholar]
  5. Emile JF. Les tumeurs stromales gastro-intestinales (GIST). Med Sci (Paris) 2013 ; 29 : 630–633. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]
  6. Letouze E, Martinelli C, Loriot C, et al. SDH Mutations establish a hypermethylator phenotype in paraganglioma. Cancer Cell 2013 ; 23 : 739–752. [CrossRef] [PubMed] [Google Scholar]
  7. Eisenhofer G, Pacak K, Huynh TT, et al. Catecholamine metabolomic and secretory phenotypes in phaeochromocytoma. Endocr Relat Cancer 2011 ; 18 : 97–111. [CrossRef] [PubMed] [Google Scholar]
  8. Loriot C, Burnichon N, Gadessaud N, et al. Epithelial to mesenchymal transition is activated in metastatic pheochromocytomas and paragangliomas caused by SDHB gene mutations. J Clin Endocrinol Metab 2012 ; 97 : E954–E962. [CrossRef] [PubMed] [Google Scholar]
  9. Pastor WA, Aravind L, Rao A. TETonic shift : biological roles of TET proteins in DNA demethylation and transcription. Nat Rev Mol Cell Biol 2013 ; 14 : 341–356. [CrossRef] [MathSciNet] [PubMed] [Google Scholar]
  10. Turcan S, Rohle D, Goenka A, et al. IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype. Nature 2012 ; 483 : 479–483. [CrossRef] [PubMed] [Google Scholar]
  11. Xu W, Yang H, Liu Y, et al. Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of alpha-ketoglutarate-dependent dioxygenases. Cancer Cell 2011 ; 19 : 17–30. [CrossRef] [PubMed] [Google Scholar]
  12. Xiao M, Yang H, Xu W, et al. Inhibition of alpha-KG-dependent histone and DNA demethylases by fumarate and succinate that are accumulated in mutations of FH and SDH tumor suppressors. Genes Dev 2012 ; 26 : 1326–1338. [CrossRef] [PubMed] [Google Scholar]
  13. Yang M, Soga T, Pollard PJ. Oncometabolites : linking altered metabolism with cancer. J Clin Invest 2013 ; 123 : 3652–3658. [CrossRef] [PubMed] [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.